



(51) International Patent Classification:

G01N 33/68 (2006.01) G01N 1/34 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2022/033517

(22) International Filing Date:

15 June 2022 (15.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/210,939 15 June 2021 (15.06.2021) US

(71) Applicant: CHASE THERAPEUTICS CORPORATION [US/US]; 1825 K Street NW, Suite 520, Washington, District of Columbia 20006 (US).

(72) Inventors: CHASE, Thomas N.; 1825 K Street NW, Suite 520, Washington, District of Columbia 20006 (US).
CLARENCE-SMITH, Kathleen; 1825 K Street NW, Suite 520, Washington, District of Columbia 20006 (US).


(74) Agent: STORELLA, John et al.; Storella & Witt, LLP, 2625 Alcatraz Ave. #197, Berkeley, California 94705 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: DIAGNOSTIC INDICES FOR NEURODEGENERATIVE CONDITIONS

Fig. 1



(57) Abstract: A method to evaluate individuals with certain neurodegenerative diseases (e.g., Parkinson's Disease) in relation to etiologic diagnosis, prognosis and response to therapy involving the noninvasive collection of a biologic sample (e.g., venous blood), isolation of small, neuronally-derived, extracellular vesicles (e.g., exosomes), assay of their external and/or internal contents for quantities of informative biomarkers (e.g., signaling kinases, catalytic proteins and miRNA species) for the construction of a diagnostic/prognostic/response algorithms of clinical utility.

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*